Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

34 trials with published results (18%)

Research Maturity

91 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.3%

12 terminated out of 190 trials

Success Rate

88.3%

+1.8% vs benchmark

Late-Stage Pipeline

18%

34 trials in Phase 3/4

Results Transparency

37%

34 of 91 completed with results

Key Signals

34 with results88% success12 terminated

Data Visualizations

Phase Distribution

145Total
Not Applicable (63)
Early P 1 (1)
P 1 (10)
P 2 (37)
P 3 (23)
P 4 (11)

Trial Status

Completed91
Unknown25
Recruiting25
Active Not Recruiting13
Terminated12
Not Yet Recruiting9

Trial Success Rate

88.3%

Benchmark: 86.5%

Based on 91 completed trials

Clinical Trials (190)

Showing 20 of 20 trials
NCT06096857Phase 2Recruiting

Cardamom and Topical Roseomonas in Atopic Dermatitis

NCT07463079Not ApplicableCompletedPrimary

Clinical Evaluation of a Soothing Moisturizing Lotion in Individuals With Atopic Eczema

NCT05735483Phase 3Enrolling By Invitation

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359Phase 3Active Not Recruiting

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07734415Phase 2Enrolling By Invitation

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

NCT01631617Phase 2RecruitingPrimary

Effects of Treatments on Atopic Dermatitis

NCT06807268Phase 3RecruitingPrimary

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT04818138Not ApplicableTerminated

BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort

NCT05990725Phase 3Completed

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT00605878RecruitingPrimary

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT07700745Not ApplicableActive Not RecruitingPrimary

A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

NCT07703215Not ApplicableCompletedPrimary

NPQ Plus Supplementation for Skin Health and Antioxidant Status

NCT06998446RecruitingPrimary

Sodium in the Skin and Atopic Dermatitis

NCT05689151Recruiting

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.

NCT06353087Active Not Recruiting

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

NCT06702293Not ApplicableRecruitingPrimary

Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients

NCT07481019Not ApplicableNot Yet Recruiting

A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology

NCT06999941Enrolling By Invitation

A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features

NCT07447063Phase 4Not Yet RecruitingPrimary

The Impact of Dietary Salt on the Severity of Eczema

NCT00798226Phase 1Active Not Recruiting

Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood

Scroll to load more

Research Network

Activity Timeline